1 results match your criteria: "Department of Clinical Oncology Maria Sklodowska-Curie National Research Institute of Oncology Krakow Poland.[Affiliation]"
Clinical bleeding events are reported here from 773 patients with B-cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence of antithrombotic therapy (antithrombotic exposed [AT-E], = 216; antithrombotic nonexposed [AT-NE], = 557). Among the AT-E cohort, 51.
View Article and Find Full Text PDF